



EXPRESS MAIL NO. EV207709506US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Donald S. Karanewsky et al.
Application No. : 09/765,105
Filed : January 16, 2001
For : C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS
INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE
PROTEASES

RECEIVED
JUN 25 2003
TECH CENTER 1600/2900

Examiner : David Lukton
Art Unit : 1653
Docket No. : 480140.442C1
Date : June 20, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references, as required under 37 C.F.R. § 1.98, are enclosed). References AE, AF, and AH-AK were cited in a search report for a related application PCT/US02/01538, mailed February 14, 2003, a copy of which is enclosed. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

We hereby certify that each of the references set forth on the attached form PTO-1449 was cited in a communication from a foreign patent office in a counterpart foreign


application not more than three months prior to the filing of this Information Disclosure Statement.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Donald S. Karanewsky et al.

Seed Intellectual Property Law Group PLLC



Karl R. Hermanns

Registration No. 33,507

Enclosures:

Form PTO-1449

Copy of Search Report

Cited References (19)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

D:\480140.442C1\364949_1.DOC

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
480140.442C1APPLICATION NO.
09/765,105INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)APPLICANTS
Donald S. Karanewsky et al.FILING DATE
January 16, 2001GROUP ART UNIT
1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILED DATE IF APPROPRIATE
	AA	6,235,899	05/22/01	Bouchet et al.	540	500	
	AB						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AE	WO 97/22619	06/26/97	WIPO		
	AF	WO 98/10778	03/19/98	WIPO		
	AG	WO 99/03852	01/28/99	WIPO (+ English Translation)	X	
	AH	WO 00/01666	01/13/00	WIPO		
	AI	WO 00/23421	04/27/00	WIPO		
	AJ	WO 01/00658	01/04/01	WIPO		
	AK	WO 01/51462	07/19/01	WIPO		
	AL	WO 01/81330	11/01/01	WIPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Chapman K., "Synthesis of a Potent, Reversible Inhibitor of Interleukin-1 β Converting Enzyme," <i>Bioorganic & Medicinal Chemistry Letters</i> 2(6):613-618, 1992.
	AN	Cheung et al., "Synthesis of 3-Amino-3-Vinylpropanoic Acid and its Conversion to 4-Amino-5-Hydroxy-4,5-Dihydrofuran-2-one Hydrochloride (HAD), A Cyclic Stabilised Form of Aspartate 1-Semialdehyde Hydrochloride," <i>Tetrahedron</i> 53(46):15807-15812, 1997.
	AO	de Lange et al., "Asymmetric 1, 4-Additions to 5-Alkoxy-2(5H)-Furanones Enantioselective Synthesis and Absolute Configuration Determination of β -Amino- γ -Butyrolactones and Amino Diols," <i>Tetrahedron</i> 45(21):6799-6818, 1989.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)

JUN 20 2003

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
480140.442C1APPLICATION NO.
09/765,105

APPLICANTS

Donald S. Karanewsky et al.

FILING DATE

January 16, 2001

GROUP AND UNIT

1653

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	AGING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BE					
	BF					
	BG					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BH	Faber et al., "Catalytic Kinetic Resolution of 5-Alkoxy-2(5H)-Furanones," <i>Tetrahedron</i> 50(16):4775-4794, 1994.
	BI	Feringa et al., "Asymmetric Synthesis of 2-Amino-1, 4-Diols," <i>Tetrahedron Letters</i> 29(11):1303-1306, 1988.
	BJ	Feringa et al., "1, 4-Additions of Amines to 5-Methoxyfuran-2(5H)-One; An Efficient Synthesis of Amino Diols," <i>Heterocycles</i> 27(5):1197-1205, 1988.
	BK	Furuichi et al., "Common Synthetic Strategy for Optically Active Cyclic Terpenoids having a 1,1,5-Trimethyl- <i>Trans</i> -Decalin Nucleus: Syntheses of (+)-Acuminolide, (-)-Spongianolide A, and (+)-Scalarenedial," <i>Tetrahedron</i> 57, pp. 8425-8442, 2001.
	BL	Gonzalez et al., "Pseudoesters and Derivatives. Part38. ¹ 1,3-Dipolar Cycloadditions of Aryl Azides and an Aziridine, <i>Via</i> Azomethine Ylide, to 2(5H)-Furanones Substituted at the 5-Position by Methoxy and Sulfur Bearing Groups," <i>Heterocycles</i> 52(1):237-251, 2000.
	BM	Leblanc et al., "Sar in the Alkoxy Lactone Series: The Discovery of DFP, A Potent and Orally Active Cox-2 Inhibitor," <i>Bioorganic & Medicinal Chemistry Letters</i> 9, pp. 2207-2212, 1999.
	BN	Lubben et al., "Asymmetric Synthesis of β -Lactams via Amine Additions to 5(R)-Menthylloxy-2[5H]-Furanone," <i>Tetrahedron: Asymmetry</i> 2(8):775-778, 1991.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).